secwatch / observer
8-K filed May 13, 2022, 7:59 PM ET ticker KZR CIK 0001645666
leadership confidence high sentiment neutral materiality 0.60

Chairman Jean-Pierre Sommadossi resigns; Graham Cooper appointed Chairman of Kezar Life Sciences

Kezar Life Sciences, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jean-Pierre Sommadossi

Chairman of the Board of Directors
KZR · Kezar Life Sciences, Inc.
Effective
2022-05-11
Successor
Graham Cooper
Filed
May 13, 2022, 7:59 PM ET
On May 11, 2022, Jean-Pierre Sommadossi, Ph.D., Chairman of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) tendered his resignation from the Board effective immediately.
Appointed

Graham Cooper

Chairman of the Board
KZR · Kezar Life Sciences, Inc.
Effective
2022-05-12
Filed
May 13, 2022, 7:59 PM ET
the Board appointed current director Graham Cooper as Chairman of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Pierre Sommadossi resigned as Chairman of the Board of Directors at Kezar Life Sciences, Inc..

Action
resigned
Role
Chairman of the Board of Directors
Exact text from the filing
On May 11, 2022, Jean-Pierre Sommadossi, Ph.D., Chairman of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) tendered his resignation from the Board effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Graham Cooper was appointed as Chairman of the Board at Kezar Life Sciences, Inc..

Action
appointed
Role
Chairman of the Board
Exact text from the filing
the Board appointed current director Graham Cooper as Chairman of the Board
View on SEC.gov

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-22-009882
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.